Sign in
WithdrawnPhase 2

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

Key facts

Who runs it
Palo Alto Veterans Institute for Research
Where
Palo Alto, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Jan 2023
Ended
Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Formoterol A
  • Formoterol B (placebo)
Record updated
16 September 2020
Why it stopped
Funding ran out before study started, prior PI left institution.

Who can take part

Age
50 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Males and females between the ages of 50-85,
  • Mild-to-moderate AD (NINCDS/ADRDA criteria for probable AD will be used to establish AD diagnosis)
  • MMSE 16-26

Who cannot take part

  • Use of another beta2 adrenergic drug within the last 2 months
  • Known hypersensitivity or prior exposure to formoterol
  • Non-AD dementia or significant neurological disease such as Parkinson's disease, stroke, brain tumor,multiple sclerosis, seizure disorder, focal brain lesion, or head injury with loss of consciousness
  • Active asthma or family history of asthma
  • Hypothyroidism, congestive heart failure (New York Heart Association Class III or IV), significant extrapyramidal symptoms on neurological examination, serum creatinine>1.3 mg/dl, significant arrhythmias or conduction defect abnormalities on ECG,
  • Evidence of any significant clinical disorder or laboratory finding that renders the person unsuitable for receiving an investigational new drug
  • Residence in a long-term care facility

Where in United States

  • VA Palo Alto Health Care SystemPalo Alto, United States

About the trial

What the trial wants to find out

The purpose of this study is to test the effects of long-term therapeutic doses of formoterol, on a) cerebrospinal fluid (CSF) tau levels, and Amyloid Beta protein 40/42 levels in the CSF, and b) cognitive function in people with mild to moderate Alzheimer' Disease (AD).

The 2 groups in the trial

  • Formoterol AExisting treatment, for comparison

    12 months, formoterol, 20microgram/2ml, inhaler, BID

  • Formoterol BPlacebo, for comparison

    12 months, normal saline, 2ml, inhaler, BID

    Treatment: Formoterol B (placebo)

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 September 2020